Beobachtungsplan, NIS 667: Prospective, multicenter, non-interventional study to evaluate patient and healthcare provider satisfaction of daratumumab use in the treatment of first-line daratumumab, lenalidomide, dexamethasone (DRd) multiple myeloma patients as per routine clinical practice in Germany depending on application route (sc or iv)

Datei

• Artikel "Beobachtungsplan, NIS 667: Prospective, multicenter, non-interventional study to evaluate patient and healthcare provider satisfaction of daratumumab use in the treatment of first-line daratumumab, lenalidomide, dexamethasone (DRd) multiple myeloma patients as per routine clinical practice in Germany depending on application route (sc or iv)"Herunterladen(PDF, 1MB, Datei ist nicht barrierefrei)